JointCouncil of Allergy, Asthma&Immunology, 50NBrockway St, #3-3, Palatine, IL 60067, USA.
J Allergy Clin Immunol. 2010 Sep;126(3):477-80.e1-42. doi: 10.1016/j.jaci.2010.06.022. Epub 2010 Aug 7.
These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing "The Diagnosis and Management of Anaphylaxis Practice Parameter: 2010 Update." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, or the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.
这些参数是由实践参数联合工作组制定的，代表了美国过敏、哮喘与免疫学学会（AAAAI）；美国过敏、哮喘与免疫学学会（ACAAI）；以及过敏、哮喘与免疫学联合委员会。AAAAI 和 ACAAI 共同承担了“过敏反应诊断与管理实践参数：2010 更新版”的建立责任。这是目前为止一份完整且全面的文件。医疗环境是一个不断变化的环境，并非所有建议都适用于所有患者。由于本文件凝聚了众多参与者的努力，包括联合工作组的成员在内，没有任何个人被授权对这些实践参数做出 AAAAI 或 ACAAI 的官方解释。有关这些实践参数的任何信息请求或解释，都应向 AAAAAI、ACAAI 或过敏、哮喘与免疫学联合委员会的执行办公室提出。这些参数不是为制药公司在药品推广中使用而设计的。
